Brain Cholesterol: Long Secret Life behind a Barrier

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 24, Issue 5, 2004, Pages 806-815

  Björkhem, Ingemar ^a   Meaney, Steve ^a   Fogelman, Alan M ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer disease; Blood brain barrier; Brain cholesterol; Cholesterol 24S hydroxylase; Statins

Indexed keywords

24 HYDROXYCHOLESTEROL; APOLIPOPROTEIN; CHOLESTEROL; CHOLESTEROL DERIVATIVE; CYTOCHROME P450; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; MYELIN; OXYSTEROL; PRAVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN LEVEL; BRAIN METABOLISM; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; DEGENERATIVE DISEASE; HOMEOSTASIS; HUMAN; PRIORITY JOURNAL; SHORT SURVEY; STEADY STATE;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CHOLESTEROL; HOMEOSTASIS; HUMANS; HYDROXYCHOLESTEROLS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MEMBRANE LIPIDS; MYELIN SHEATH; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; RATS; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 2442557294     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000120374.59826.1b     Document Type: Short Survey

References (113)

1. Couerbe JP. Du Cerveau, considéré sous le point du vue chimique et physiologique. Annales de Chimie et de Physique. 1834;56:160-193.
2. Raffai RL, Weisgraber KH. Cholesterol: from heart attacks to Alzheimer's disease. J Lipid Res. 2003;44:1423-1430.
3. Snipes G, Suter U. Cholesterol and Myelin. In: Bittman R, ed. Cholesterol. New York: Plenum Press; 1998.
4. Dietschy JM, Turley SD. Cholesterol metabolism in the brain. Curr Opin Upidol. 2001;12:105-112.
5. Björkhem I, Lutjohann D, Diczfalusy U, Stahle L, Ahlborg G, Wahren J. Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. J Lipid Res. 1998;39:1594-1600.
6. Xie C, Lund EG, Turley SD, Russell DW, Dietschy JM. Quantitation of two pathways for cholesterol excretion from the brain in normal mice and mice with neurodegeneration. J Lipid Res. 2003;44:1780-1789.
7. Barenholz Y. Cholesterol and other membrane active sterols: from membrane evolution to "rafts." Prog Lipid Res. 2002;41:1-5.
8. Bittman R. Has nature designed the cholesterol side chain for optimal interaction with phospholipids? Subcell Biochem. 1997;28:145-171.
9. Tint G, Batta A, Xu G, Shefer S, Honda A, Irons M, Elias E, Salen G. The Smith-Lemli-Opitz syndrome: A potentially fatal birth defect caused by a block in the last enzymatic step in cholesterol biosynthesis. In: Bittman R, ed. Cholesterol. New York: Plenum Press; 1998.
10. Jira PE, Waterham HR, Wanders RJ, Smeitink JA, Sengers RC, Wevers RA. Smith-Lemli-Opitz syndrome and the DHCR7 gene. Ann Hum Genet. 2003;67:269-280.
11. Wechsler R, Brafman A, Shafir M, Heverin M, Gottlieb H, Damari G, Gozlan-Kelner S, Spikvak I, Moshkin O, Fridman E, Becker Y, Skaliter R, Einat P, Faerman A, Björkhem I, Feinstein E. Generation of viable cholesterol-free mouse. Science. 2003;302:2087.
12. Waelsch H, Sperry W, Stoyanoff VA. A study of the synthesis and deposition of lipids in brain and other tissues with deuterium as an indicator. J Biol Chem 1940;135:291-296.
13. Bloch K, Berg B, Rittenberg D. The biological conversion of cholesterol to cholic acid. J Biol Chem 1943;149:511-517.
14. Jurevics H, Morell P. Cholesterol for synthesis of myelin is made locally, not imported into brain. J Neurochem. 1995;64:895-901.
15. Chobanian A, Hollander W. Body cholesterol metabolism in man. I The equilibration of serum and tissue cholesterol. J Clin Invest. 1962;41:1732-1737.
16. Meaney S, Hassan M, Sakinis A, Lutjohann D, von Bergmann K, Wennmalm A, Diczfalusy U, Björkhem I. Evidence that the major oxysterols in human circulation originate from distinct pools of cholesterol: a stable isotope study. J Lipid Res. 2001;42:70-78.
17. Plotz E, Kabara J, Davis M, LeRoy G, Gould RG. Studies on the synthesis of cholesterol in the brain of the human fetus. Am J Obstet Gynecol. 1968;101:534-538.
18. Reese TS, Karnovsky MJ. Fine structural localization of a blood-brain barrier to exogenous peroxidase. J Cell Biol. 1967;34:207-217.
19. Dehouck B, Dehouck MP, Fruchart JC, Cecchelli R. Upregulation of the low density lipoprotein receptor at the blood-brain barrier: intercommunications between brain capillary endothelial cells and astrocytes. J Cell Biol. 1994;126:465-473.
20. Dehouck B, Fenart L, Dehouck MP, Pierce A, Torpier G, Cecchelli R. A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier. J Cell Biol. 1997;138:877-889.
21. Panzenboeck U, Balazs Z, Sovic A, Hrzenjak A, Levak-Frank S, Wintersperger A, Malle E, Sattler W. ABCA1 and scavenger receptor class B, type I, are modulators of reverse sterol transport at an in vitro blood-brain barrier constituted of porcine brain capillary endothelial cells. J Biol Chem 2002;277:42781-42789.
22. Saito M, Benson EP, Rosenberg A. Metabolism of cholesterol and triacylglycerol in cultured chick neuronal cells, glial cells, and fibroblasts: accumulation of esterified cholesterol in serum-free culture. J Neurosci Res. 1987;18:319-325.
23. Koper JW, Zeinstra EC, Lopes-Cardozo M, van Golde LM. Acetoacetate and glucose as substrates for lipid synthesis by rat brain oligodendrocytes and astrocytes in serum-free culture. Biochim Biophys Acta. 1984;796:20-26.
24. Pfrieger FW. Outsourcing in the brain: do neurons depend on cholesterol delivery by astrocytes? Bioessays. 2003;25:72-78.
25. Mauch DH, Nagler K, Schumacher S, Goritz C, Muller EC, Otto A, Pfrieger FW. CNS synaptogenesis promoted by glia-derived cholesterol. Science. 2001;294:1354-1357.
26. Pfrieger FW. Role of cholesterol in synapse formation and function. Biochim Biophys Acta. 2003;1610:271-280.
27. Volpe JJ, Obert KA. Coordinate regulation of cholesterol synthesis and 3-hydroxy-3-methylglutaryl coenzyme A synthase but not 3-hydroxy-3-methylglutaryl coenzyme A reductase in C-6 glia. Arch Biochem Biophys. 1981;212:88-97.
28. Birkenmeier G, Grosche J, Reichenbach A. Immunocytochemical demonstration of alpha 2-M-R/LRP on Muller (glial) cells isolated from rabbit and human retina. Neuroreport. 1996;8:149-151.
29. Jung-Testas I, Weintraub H, Dupuis D, Eychenne B, Baulieu EE, Robel P. Low density lipoprotein-receptors in primary cultures of rat glial cells. J Steroid Biochem Mol Biol 1992;42:597-605.
30. Norton W. Isolation and characterisation of myelin. In: Bittman R, ed. Cholesterol. New York: Plenum Press; 1998.
31. Boyles JK, Pitas RE, Wilson E, Mahley RW, Taylor JM. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nommyelinating glia of the peripheral nervous system. J Clin Invest. 1985;76:1501-1513.
32. Shanmugaratnam J, Berg E, Kimerer L, Johnson RJ, Amaratunga A, Schreiber BM, Fine RE. Retinal Muller glia secrete apolipoproteins E and J which are efficiently assembled into lipoprotein particles. Brain Res Mol Brain Res. 1997;50:113-120.
33. Pitas RE, Boyles JK, Lee SH, Hui D, Weisgraber KH. Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. J Biol Chem 1987;262:14352-14360.
34. Danik M, Champagne D, Petit-Turcotte C, Beffert U, Poirier J. Brain lipoprotein metabolism and its relation to neurodegenerative disease. Crit Rev Neurobiol. 1999;13:357-407.
35. Hofmann SL, Russell DW, Goldstein JL, Brown MS. mRNA for low density lipoprotein receptor in brain and spinal cord of immature and mature rabbits. Proc Natl Acad Sci U S A. 1987;84:6312-6316.
36. Swanson LW, Simmons DM, Hofmann SL, Goldstein JL, Brown MS. Localization of mRNA for low density lipoprotein receptor and a cholesterol synthetic enzyme in rabbit nervous system by in situ hybridization. Proc Natl Acad Sci USA. 1988;85:9821-9825.
37. Bu G, Maksymovitch EA, Nerbonne JM, Schwartz AL. Expression and function of the low density lipoprotein receptor-related protein (LRP) in mammalian central neurons. J Biol Chem 1994;269:18521-18528.
38. Herz J, Bock HH. Lipoprotein receptors in the nervous system. Annu Rev Biochem 2002;71:405-434.
39. Osono Y, Woollett LA, Herz J, Dietschy JM. Role of the low density lipoprotein receptor in the flux of cholesterol through the plasma and across the tissues of the mouse. J Clin Invest. 1995;95:1124-1132.
40. Masliah E, Mallory M, Ge N, Alford M, Veinbergs I, Roses AD. Neurodegeneration in the central nervous system of apoE-deficient mice. Exp Neurol. 1995;136:107-122.
41. Mato M, Ookawara S, Mashiko T, Sakamoto A, Mato TK, Maeda N, Kodama T. Regional difference of lipid distribution in brain of apolipoprotein E deficient mice. Anat Rec. 1999;256:165-176.
42. Trommsdorff M, Gotthardt M, Hiesberger T, Shelton J, Stockinger W, Nimpf J, Hammer RE, Richardson JA, Herz J. Reeler/Disabled-like disruption of neuronal migration in knockout mice lacking the VLDL receptor and ApoE receptor 2. Cell. 1999;97:689-701.
43. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993;43:1467-1472.
44. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921-923.
45. Teasdale GM, Nicoll JA, Murray G, Fiddes M. Association of apolipoprotein E polymorphism with outcome after head injury. Lancet. 1997;350:1069-1071.
46. Gong JS, Kobayashi M, Hayashi H, Zou K, Sawamura N, Fujita SC, Yanagisawa K, Michikawa M. Apolipoprotein E (ApoE) isoform-dependent lipid release from astrocytes prepared from human ApoE3 and ApoE4 knock-in mice. J Biol Chem. 2002;277:29919-29926.
47. Sun Y, Wu S, Bu G, Onifade MK, Patel SN, LaDu MJ, Fagan AM, Holtzman DM. Glial fibrillary acidic protein-apolipoprotein E (apoE) transgenic mice: astrocyte-specific expression and differing biological effects of astrocyte-secreted apoE3 and apoE4 lipoproteins. J Neurosci. 1998;18:3261-3272.
48. Schmitz G, Kaminski WE. ABCA2: a candidate regulator of neural transmembrane lipid transport. Cell Mol Life Sci. 2002;59:1285-1295.
49. Zhou C, Zhao L, Inagaki N, Guan J, Nakajo S, Hirabayashi T, Kikuyama S, Shioda S. Atp-binding cassette transporter ABC2/ABCA2 in the rat brain: a novel mammalian lysosome-associated membrane protein and a specific marker for oligodendrocytes but not for myelin sheaths. J Neurosci. 2001;21:849-857.
50. Tanaka Y, Yamada K, Zhou CJ, Ban N, Shioda S, Inagaki N. Temporal and spatial profiles of ABCA2-expressing oligodendrocytes in the developing rat brain. J Comp Neurol. 2003;455:353-367.
51. Pitas RE, Boyles JK, Lee SH, Foss D, Mahley RW. Astrocytes synthesize apolipoprotein E and matabolize apolipoprotein E-containing lipoproteins. Biochim Biophys Acta. 1987;917:148-161.
52. Björkhem I, Lutjohann D, Breuer O, Sakinis A, Wennmalm A. Importance of a novel oxidative mechanism for elimination of brain cholesterol. Turnover of cholesterol and 24(S)-hydroxycholesterol in rat brain as measured with 18O2 techniques in vivo and in vitro. J Biol Chem. 1997;272:30178-30184.
53. Lutjohann D, Breuer O, Ahlborg G, Nennesmo I, Siden A, Diczfalusy U, Björkhem I. Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc Natl Acad Sci U S A. 1996;93:9799-9804.
54. Kessel A, Ben-Tal N, May S. Interactions of cholesterol with lipid bilayers: the preferred configuration and fluctuations. Biophys J. 2001;81:643-658.
55. Meaney S, Bodin K, Diczfalusy U, Björkhem I. On the rate of translocation in vitro and kinetics in vivo of the major oxysterols in human circulation: critical importance of the position of the oxygen function. J Lipid Res. 2002;43:2130-2135.
56. Lange Y, Ye J, Strebel F. Movement of 25-hydroxycholesterol from the plasma membrane to the rough endoplasmic reticulum in cultured hepatoma cells. J Lipid Res. 1995;36:1092-1097.
57. Lund EG, Guileyardo JM, Russell DW. cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc Natl Acad Sci USA. 1999;96:7238-7243.
58. Meaney S, Lutjohann D, Diczfalusy U, Björkhem I. Formation of oxysterols from different pools of cholesterol as studied by stable isotope technique: cerebral origin of most circulating 24S-hydroxycholesterol in rats, but not in mice. Biochim Biophys Acta. 2000;1486:293-298.
59. Lund EG, Xie C, Kotti T, Turley SD, Dietschy JM, Russell DW. Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover. J Biol Chem. 2003;278:22980-22988.
60. Bogdanovic N, Bretillon L, Lund EG, Diczfalusy U, Lannfelt L, Winblad B, Russell DW, Björkhem I. On the turnover of brain cholesterol in patients with Alzheimer's disease. Abnormal induction of the cholesterol-catabolic enzyme CYP46 in glial cells. Neurosci Lett. 2001;314:45-48.
61. Bretillon L, Lutjohann D, Stahle L, Widhe T, Bindl I, Eggertsen G, Diczfalusy U, Björkhem I. Plasma levels of 24S-hydroxycholesterol reflect the balance between cerebral production and hepatic metabolism and are inversely related to body surface. J Lipid Res. 2000;41:840-845.
62. Leoni V, Masterman T, Diczfalusy U, De Luca G, Hillert J, Björkhem I. Changes in human plasma levels of the brain specific oxysterol 24S-hydroxycholesterol during progression of multiple sclerosis. Neurosci Lett. 2002;331:163-166.
63. Bretillon I, Siden A, Wahlund LO, Lutjohann D, Minthon L, Crisby M, Hillert J, Groth CG, Diczfalusy U, Björkhem I. Plasma levels of 24S-hydroxycholesterol in patients with neurological diseases. Neurosci Lett. 2000;293:87-90.
64. Lutjohann D, Papassotiropoulos A, Björkhem I, Locatelli S, Bagli M, Oehring RD, Schlegel U, Jessen F, Rao ML, von Bergmann K, Heun R. Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J Lipid Res. 2000;41:195-198.
65. Babiker A, Diczfalusy U. Transport of side-chain oxidized oxysterols in the human circulation. Biochim Biophys Acta 1998;1392:333-339.
66. Edwards PA, Kennedy MA, Mak PA. LXRs; oxysterol-activated nuclear receptors that regulate genes controlling lipid homeostasis. Vascul Pharmacol. 2002;38:249-256.
67. Repa JJ, Mangelsdorf DJ. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu Rev Cell Dev Biol. 2000;16:459-481.
68. Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature. 1996;383:728-731.
69. Lehmann JM, Kliewer SA, Moore LB, Smith-Oliver TA, Oliver BB, Su JL, Sundseth SS, Winegar DA, Blanchard DE, Spencer TA, Willson TM. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J Biol Chem. 1997;272:3137-3140.
70. Whitney KD, Watson MA, Collins JL, Benson WG, Stone TM, Numerick MJ, Tippin TK, Wilson JG, Winegar DA, Kliewer SA. Regulation of cholesterol homeostasis by the liver X receptors in the central nervous system. Mol Endocrinol. 2002;16:1378-1385.
71. Björkhem I. Do oxysterols control cholesterol homeostasis? J Clin Invest. 2002;110:725-730.
72. Meaney S. Studies on Oxysterols: Origins. Properties and Roles Laboratory Medicine. Stockholm; 2003.
73. Teboul M, Enmark E, Li Q, Wikstrom AC, Pelto-Huikko M, Gustafsson JA. OR-1, a member of the nuclear receptor superfamily that interacts with the 9-cis-retinoic acid receptor. Proc Natl Acad Sci U S A. 1995;92:2096-2100.
74. Kainu T, Kononen J, Enmark E, Gustafsson JA, Pelto-Huikko M. Localization and ontogeny of the orphan receptor OR-1 in the rat brain. J Mol Neurosci. 1996;7:29-39.
75. Wang L, Schuster GU, Hultenby K, Zhang Q, Andersson S, Gustafsson JA. Liver X receptors in the central nervous system: from lipid homeostasis to neuronal degeneration. Proc Natl Acad Sci U S A. 2002;99:13878-13883.
76. Burns M, Duff K. Cholesterol in Alzheimer's disease and autopathy. Ann N Y Acad Sci. 2002;977:367-375.
77. Sparks DL, Scheff SW, Hunsaker JC, 3rd, Liu H, Landers T, Gross DR. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol. 1994;126:88-94.
78. Rubinstein DC, Easton DF. Apolipoprotein E genetic variation and Alzheimer's disease. a meta-analysis. Dement Geriatr Cogn Disord. 1999;10:199-209.
79. Wisniewski T, Frangione B. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett. 1992;135:235-238.
80. Strittmatter WJ. Apolipoprotein E and Alzheimer's disease: signal transduction mechanisms. Biochem Soc Symp. 2001;67:101-109.
81. Kirsch C, Eckert GP, Koudinov AR, Muller WE. Brain cholesterol, statins and Alzheimer's disease. Pharmacopsychiatry. 2003;36:113-119.
82. Simons M, Keller P, Dichgans J, Schulz JB. Cholesterol and Alzheimer's disease: is there a link? Neurology. 2001;57:1089-1093.
83. Bodovitz S, Klein WL. Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J Biol Chem. 1996;271:4436-4440.
84. Frears ER, Stephens DJ, Walters CE, Davies H, Austen BM. The role of cholesterol in the biosynthesis of beta-amyloid. Neuroreport. 1999;10:1699-1705.
85. Howland DS, Trusko SP, Savage MJ, Reaume AG, Lang DM, Hirsch JD, Maeda N, Siman R, Greenberg BD, Scott RW, Flood DG. Modulation of secreted beta-amyloid precursor protein and amyloid beta-peptide in brain by cholesterol. J Biol Chem. 1998;273:16576-16582.
86. Galbete JL, Martin TR, Peressini E, Modena P, Bianchi R, Forloni G. Cholesterol decreases secretion of the secreted form of amyloid precursor protein by interfering with glycosylation in the protein secretory pathway. Biochem J. 2000;348:307-313.
87. Liu Y, Peterson DA, Schubert D. Amyloid beta peptide alters intracellular vesicle traffickiing and cholesterol homeostasis. Proc Natl Acad Sci U S A. 1998;95:13266-13271.
88. Puglielli L, Konopka G, Pack-Chung E, Ingano LA, Berezovska O O, Hyman BT, Chang TY, Tanzi RE, Kovacs DM. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat Cell Biol. 2001;3:905-912.
89. Treiber-Held S, Distl R, Meske V, Albert F, Ohm TG. Spatial and temporal distribution of intracellular free cholesterol in brains of a Niemann-Pick type C mouse model showing hyperphosphorylated tau protein. Implications for Alzheimer's disease. J Pathol. 2003;200:95-103.
90. Xie C, Burns DK, Turley SD, Dietschy JM. Cholesterol is sequestered in the brains of mice with Niemann-Pick type C disease but turnover is increased. J Neuropathol Exp Neurol. 2000;59:1106-1117.
91. Papassotiropoulos A, Lutjhohann D, Bagli M, Locatelli S, Jessen F, Rao ML, Maier W, Björkhem I, von Bergmann K, Heun R. Plasma 24S-hydroxycholesterol: a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer's disease. Neuroreport. 2000;11:1959-1962.
92. Heverin M, Bogdanovic N, Lutjohann D, Bayer T, Pikuleva I, Bretillon L, Diczfalusy U, Winblad B, Björkhem I. Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease. J Lipid Res. 2003.
93. Lutjohann D, Brzezinka A, Barth E, Abramowski D, Staufenbiel M, von Bergmann K, Beyreuther K, Multhaup G, Bayer TA. Profile of cholesterol-related sterols in aged amyloid precursor protein transgenic mouse brain. J Lipid Res. 2002;43:1078-1085.
94. Green RC, Jayakumar P, Benke K, Farrer L. Statin use is associated with reduced risk of Alzheimer's disease. Neurobiol Aging. 2002;23:273-274.
95. Hajjar I, Schumpert J, Hirth V, Wieland D, Eleazer GP. The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol A Biol Sci Med Sci. 2002;57:M414-M418.
96. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet. 2000;356:1627-1631.
97. Rockwood K, Kirkland S, Hogan DB, MacKnight C, Merry H, Verreault R, Wolfson C, McDowell I. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol. 2002;59:223-227.
98. Rodriguez EG, Dodge HH, Birzescu MA, Stoehr GP, Ganguli M. Use of lipid-lowering drugs in older adults with and without dementia: a community-based epidemiological study. J Am Geriatr Soc. 2002;50:1852-1856.
99. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000;57:1439-1443.
100. Yaffe K, Barrett-Connor E, Lin F, Grady D. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol. 2002;59:378-384.
101. Haley RW, Dietschy JM. Is there a connection between the concentration of cholesterol circulating in plasma and the rate of neuritic plaque formation in Alzheimer disease? Arch Neurol. 2000;57:1410-1412.
102. Green RC, Cupples LA, Go R, Benke KS, Edeki T, Griffith PA, Williams M, Hipps Y, Graff-Radford N, Bachman D, Farrer LA. Risk of dementia among white and African Am relatives of patients with Alzheimer disease. JAMA. 2002;287:329-336.
103. Etminan M, Gill S, Samii A. The role of lipid-lowering drugs in cognitive function: a meta-analysis of observational studies. Pharmacotherapy. 2003;23:726-730.
104. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
105. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623-1630.
106. Locatelli S, Lutjohann D, Schmidt HH, Otto C, Beisiegel U, von Bergmann K. Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain. Arch Neurol. 2002;59:213-216.
107. Ishii K, Tokuda T, Matsushima T, Miya F, Shoji S, Ikeda S, Tamaoka A. Pravastatin at 10 mg/day does not decrease plasma levels of either amyloid-beta (Abeta) 40 or Abeta 42 in humans. Neurosci Lett. 2003;350:161-164.
108. Sjogren M, Gustafsson K, Syversen S, Olsson A, Edman A, Davidsson P, Wallin A, Blennow K. Treatment with Simvastatin in Patients with Alzheimer's Disease Lowers Both alpha- and beta-Cleaved Amyloid Precursor Protein. Dement Geriatr Cogn Disord. 2003;16:25-30.
109. Buxbaum JD, Cullen EI, Friedhoff LT. Pharmacological concentrations of the HMG-CoA reductase inhibitor lovastatin decrease the formation of the Alzheimer beta-amyloid peptide in vitro and in patients. Front Biosci. 2002;7:a50-a59.
110. Simons M, Schwarzler F, Lutjohann D, von Bergmann K, Beyreuther K, Dichgans J, Wormstall H, Hartmann T, Schulz JB. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol. 2002;52:346-350.
111. Vega GL, Weiner MF, Lipton AM, Von Bergmann K, Lutjohann D, Moore C, Svetlik D. Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. Arch Neurol. 2003;60:510-515.
112. Fassbender K, Stroick M, Bertsch T, Ragoschke A, Kuehl S, Walter S, Walter J, Brechtel K, Muehlhauser F, Von Bergmann K, Lutjohann D. Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. Neurology. 2002;59:1257-1258.
113. Park IH, Hwang EM, Hong HS, Boo JH, Oh SS, Lee J, Jung MW, Bang OY, Kim SU, Mook-Jung I. Lovastatin enhances Abeta production and senile plaque deposition in female Tg2576 mice. Neurobiol Aging. 2003;24:637-643.